STE — STERIS plc (Ireland)

Is STE overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Overbought As of August 19, 2026

STERIS plc (Ireland) (STE) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Medical Devices) last closed at $232.39. The rating moved from Neutral to Overbought on August 19, 2026.

See all overbought Healthcare stocks →

AI analysis

STERIS plc combines a defensive, recurring‑revenue industrial healthcare franchise with direct exposure to expanding biologics, CRO/CDMO and diagnostic workflows. The installed base and aftermarket services provide cash flow stability while demand drivers from biologics and screening could support equipment and service growth. Recent market rotation into growth names and dovish Fed commentary has created a constructive near‑term technical backdrop. Key challenges include hospital capital spending variability, payer/procurement pressure, regulatory and supply‑chain risks, and competitive dynamics. Overall outlook is for modest organic growth coupled with margin improvement and selective M&A upside, with sensitivity to macro and sector‑specific cycles.

Key factors

  • Leading market position in infection prevention, sterilization and surgical products with durable installed base and recurring service revenue
  • Direct exposure to biologics / CRO/CDMO and diagnostics growth through demand for fill/finish, sterilization and lab support services
  • Stable aftermarket/service revenue provides cash flow resilience versus pure capital-equipment peers
  • Proven ability to drive margins via operational improvements and pricing, plus a track record of accretive M&A to expand addressable markets
  • Constructive near-term market backdrop (risk‑on sentiment, rotation into growth) that can support multiple expansion
  • Balance sheet flexibility to invest in growth, buy back stock or execute strategic acquisitions (historical strength; actual leverage not provided here)

Risks

  • Slower capital spending by hospitals and biopharma customers in an uncertain macro environment, compressing equipment orders
  • Reimbursement, payer or procurement pressures that could reduce hospital purchasing intensity or push pricing concessions
  • Regulatory, compliance or product liability events that could result in recalls, litigation, or higher compliance costs
  • Supply‑chain disruptions or commodity cost inflation that hurt margins and delivery timelines
  • Intensifying competition from other sterilization and instrument suppliers or from alternative technologies
  • Geopolitical tensions and headline risk that could weigh investor sentiment and cross‑border operations

See today's live rating, score and targets

Members see the live hourly rating for STE — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.